Get started

Earnings

Zoetis | ZTS | Long at $156.94Zoetis NYSE:ZTS , the largest global animal health company, generated more than $9 billion in revenue in 2024 and earnings have grown 9.3% per year over the past 5 years. Free cash flow for FY2024 was over $2.2 billion. Dividend consistently raised every year for the past for years (currently 1.28%). The growth of the company isn't expected to slow any time soon, and I believe the animal health care market will grow right alongside the human health care market - if not potentially faster (people love their pets). Thus, at $156.94, NYSE:ZTS is in a personal buy zone. There may be some near-term risk with the potential for a daily price-gap close near $136.00, but I personally view that as an even better buy opportunity (unless fundamentals change). Targets $170.00 $180.00 $200.00
NYSE:ZTSLong
by WorthlessViews
Hormel Foods Co | HRL | Long at $28.98Food stocks are gaining momentum. I anticipate another round of inflation could boost them in the coming 1-2 years. Hormel NYSE:HRL is trading at a price-to-earnings of 20x and pays a dividend of 4.05%. Insiders have been awarded options and are buying shares below $30. Earnings are forecast to grow 9.16% per year and the company has a very low debt-to-equity ratio (0.36x). Thus, at $28.98, NYSE:HRL is in a personal buy zone. Targets: $34.00 $36.00 ... $50.00 (very long-term, inflationary environment, etc)
NYSE:HRLLong
by WorthlessViews
JD.COM - we had amazing earnings, waiting for the yearly report!JD.com is scheduled to release its fourth-quarter and full-year 2024 financial results on March 6, 2025.Analysts are optimistic about the company's performance, with several key indicators pointing toward positive growth: Earnings Projections: Earnings Per Share (EPS): The consensus estimate for the upcoming quarter is $0.85, reflecting an increase from last year's $0.73 for the same period. Revenue Growth: Projections indicate a year-over-year revenue growth of approximately 6.61%, with expected revenues rising from $43.11 billion to $45.96 billion. Analyst Ratings: Strong Buy Recommendation: Based on evaluations from nine analysts, JD.com has received a consensus rating of "Strong Buy," underscoring confidence in the company's growth trajectory. Future Outlook: Earnings Growth: Forecasts suggest JD.com's earnings will grow by 13% per annum, with an anticipated EPS growth rate of 12.8% annually. Revenue Projections: The company's revenue is expected to increase by 5.6% per year, indicating sustained business expansion. These positive indicators reflect JD.com's robust market position and its potential for continued growth in the upcoming earnings release. Entry: 42.00 Target 70.00
NASDAQ:JDLong
by DG55Capital
BUY $100-130 for LT holdAnalysis: - LT trend since 2012 shows ~$100 as key support level, even if support (prior resistance now support) from 2014 fails. - $100 is 67% off of the recent high of $306. Ouch! But this also means there's large upside to get back to those levels. Despite Trump admin opposition to renewables, FSLR is well positioned with US manufacturing capability, a FWB:20B backlog on current SEED_TVCODER77_ETHBTCDATA:4B in revenue. This means they could grow YoY throughout the Trump admin with just the current backlog. Also, they're profitable with 30% Net Income margins form the last year. Large commercial customers (namely, tech giants through renewables developers) are happy to continue investing billions in renewables (and to trade high capex for low opex). Investment Thesis: - Monitor this $130-135 level. If broken with conviction, we look towards $100 entry points. IMO, worst case is also $100-130 price by EOY 2026.
NASDAQ:FSLRLong
by HandsomeSloth
Salesforce - Integration of AI with great earnings = growth!Hi guys today we would be looking into Salesforce - with the upcomming Q4 earnings report it's expected for some great growth : Fundamentals below - Salesforce is poised for a promising earnings report, reflecting its robust performance and strategic advancements. In the third quarter, the company reported an 8% year-over-year revenue increase to $9.44 billion, surpassing analysts' expectations. This growth is attributed to strong client spending on its enterprise cloud services and data cloud, driven by the integration of artificial intelligence to streamline corporate workflows. The introduction of Agentforce 2.0, an advanced version of its AI agent program, allows users to deploy AI agents within the Slack app and includes enhanced features such as improved reasoning, integration, and customization. The full release is expected in February 2025. Wall Street has responded positively, with analysts maintaining optimistic projections. Salesforce plans to hire 2,000 people to promote its AI software, countering the industry trend of layoffs due to the high costs of AI projects. Salesforce's stock surged by 11% after the initial announcement and has risen 33% year-to-date, outperforming the S&P 500. Analysts anticipate continued investor enthusiasm and potential gains of up to $80 per share as more businesses adopt the platform. Analysts are optimistic about Salesforce's financial outlook. Wedbush analyst Dan Ives has raised the Q1 2026 earnings estimate to $1.90 per share, up from the prior estimate of $1.88, maintaining an "Outperform" rating with a $375 price target. The consensus estimate for Salesforce’s current full-year earnings is $7.48 per share. The company's stock performance has been strong, with shares trading at $361.99 as of the latest report. The stock has a market cap of $346.06 billion, a price-to-earnings ratio of 59.54, and a beta of 1.30. The business has a 50-day simple moving average of $309.97 and a two-hundred day simple moving average of $272.88. In summary, Salesforce's strategic focus on AI integration, strong financial performance, and positive market reception position the company for continued success in the upcoming earnings report. Target: 365 - Just below the ATH so we can have some protection of the trade SL: 294 - just below the formulated GAP which we covered
NYSE:CRMLong
by DG55Capital
Is $GERN a stock for "Strong Holders"?Or is it just another stock whose value will be wiped out in the next few quarters, and the company will simply lose its listing on the Nasdaq? Investors are likely to get an answer to this question today, before the market opens, when NASDAQ:GERN reports its quarterly earnings. The company has an approved drug and has already begun commercialization, with a promising start. Last quarter, the company generated $28 million in revenue, and this quarter, revenue is expected to reach $61.8 million. The company has already achieved positive gross margins, and I expect them to improve significantly from the current 27% in the last quarter. Operating expenses are close to $30 million per quarter, so we can expect a quick path to operating profitability. Invested capital is around $135 million, which means that with an operating profit of $10 million per quarter, we could see interesting returns on invested capital. The company is led by John A. Scarlett, M.D., who previously worked at NASDAQ:CTMX for six years, during which the company lost about 90% of its value. There is some positive news regarding European approval: "The Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion." A decision is expected in the coming months, if not days, which should serve as a strong catalyst for the stock price. The market valuation has dropped to $1.4 billion, despite having an FDA-approved drug in the U.S. Cash reserves will be important as they indicate how much time the company has to develop without diluting its capital. In the last report, cash and short-term investments totaled $339 million, and on November 7, the company announced securing $250 million in funding, with the potential to increase it to $375 million. As a result, the company has $589 million in cash reserves minus operating cash flow. How much will remain in the coffers? The company should have enough cash for more than 12 months of successful operations, operational efficiency is improving, we are awaiting European approval, and only the quality of management raises doubts. But do these doubts really hold weight given the current trajectory? There are only a few hours left until the earnings report is released. Let's see what awaits us. Strong Holders Profiting From Strength 📉✊📈
NASDAQ:GERNLong
by Strong_Holders
MSFT ChannelBetween January 2023 and July 2024 NASDAQ:MSFT had a nearly 100% expansion showing aggressive growth. For the last 8 months however, MSFT has been trading sideways in a channel between ~$455 and ~$400. During the last earnings report future growth guidance came in under expectations. Technically, there was large gap down following earnings and a retraction to the 21 EMA offering a short entry window. I took a short position here with a stop loss placed above the 21 EMA, I will be adding to this position when price breaks the support of $400 and again if it continues to fall and retracts to the $400 level. First target is the previous $373 support level, second target is the $330 support level.
NASDAQ:MSFTShort
by Notbadchad
Walmart Earnings Trade Setup: Two Key Levels to WatchWalmart ( NYSE:WMT ) has earnings coming up tomorrow, and I’m eyeing two potential trade setups depending on how the market reacts. Bullish Scenario : If Walmart pumps post-earnings, I’m targeting a move up to $115. Momentum could easily carry it to this key resistance level. Bearish Pullback & Reversal : If Walmart sells off on earnings, I’ll be looking at the $96 area as a strong level for a long entry. This zone has historical significance and could provide a solid buying opportunity. Earnings moves can be unpredictable, but these two levels give me a clear game plan. Let’s see how it plays out! What’s your take—will WMT rip or dip?
NYSE:WMTLong
by FindBetterTrades
2
BABA - The company is so back!Partnership with Apple?Hi guys, we would be looking into BABA as a structure and a future proof company, which will give us a neccesary boost towars the price increasing! Alibaba Group Holding Ltd. (BABA) has recently demonstrated remarkable growth and resilience, positioning itself as a compelling investment opportunity. As of February 18, 2025, Alibaba's stock is trading at $127.58, reflecting a significant upward trajectory. Over the past month, the stock has surged over 55%, indicating strong market confidence. A pivotal factor contributing to this momentum is Alibaba's strategic partnership with Apple. Announced on February 13, 2025, this collaboration aims to integrate Alibaba's advanced AI capabilities into iPhones sold in the Chinese market. This alliance not only enhances the user experience but also solidifies Alibaba's position in the AI sector. Furthermore, Alibaba's commitment to innovation is evident in its restructuring efforts. The company's "1+6+N" plan, unveiled in March 2023, reorganized its operations into six independently managed entities. This strategic move has empowered each unit to pursue growth autonomously, fostering agility and responsiveness in a dynamic market. Analysts remain optimistic about Alibaba's future. The average 12-month price target stands at $129.13, with projections reaching as high as $151.00. This optimism is underpinned by Alibaba's robust earnings growth forecast of 11.1% per annum and a revenue growth rate of 6.3% per annum. TIPRANKS.COM In summary, Alibaba's strategic initiatives, innovative partnerships, and strong financial outlook underscore its potential for sustained growth, making it an attractive prospect for investors.
NYSE:BABALong
by DG55Capital
1
PARAMOUNT - EPS Beat 12 out of 17 Q's can we extract potential?Hi guys we are going to take a look into Paramount and see if we can extract some potential from this stock! Fundamentals&Technicals below - As of February 15, 2025, Paramount Global's Class B stock (ticker: PARA) is trading at $11.30 per share, reflecting a 4.5% increase from the previous close. This marks the fourth consecutive day of gains, though the stock remains 22.3% below its 52-week high of $14.54 achieved on May 3, 2024. In the third quarter of 2024, Paramount reported net income of $1 million, a significant decline from $295 million in the same period the previous year. Earnings per share reached breakeven, missing analyst expectations of 24 cents. Total revenue decreased to $6.731 billion from $7.133 billion, influenced by a 6% drop in TV media revenue and a 34% decline in filmed entertainment revenue.Despite these challenges, the company's streaming segment showed resilience. Paramount+ added 3.5 million subscribers in the third quarter, bringing the total to 72 million. The streaming service reported an adjusted operating income of $49 million, defying analysts' predictions of a $160.1 million loss. In 2024, Paramount undertook significant restructuring efforts, including a $6 billion write-down of its cable-TV business and the elimination of approximately 2,000 jobs, representing about 15% of its U.S. workforce. These measures aim to achieve $500 million in cost savings and address challenges in the traditional TV sector. Looking ahead, Paramount is set to merge with Skydance Media, with the merger expected to complete in early 2025. This strategic move is anticipated to inject significant capital into Paramount, aiding in debt reduction and enabling investments in new content and technologies. Entry: on market open Target: 17.00 just below the weak resistance. SL: 7.50 P.S. We are sitting on a very key support area which has been overviewd long term which is around the 9.00 and 11.00 area, so this gives us additional confidence in the stock increasing.Hopefully the positive earnings report will have another beat in EPS, and would yield great value.
NASDAQ:PARALong
by DG55Capital
COINBASE - Can the great crypto bull run repeat good EPS?Hi guys we are going to have an overlook of Coinbase before their earnings so we can try and extract some great value! Coinbase Global, Inc. (COIN) is set to release its fourth-quarter 2024 earnings report on February 13, 2025. Analysts are optimistic, anticipating significant growth driven by increased trading volumes and strategic initiatives. According to Coin Metrics, Coinbase's trading volumes reached approximately $430 billion in Q4 2024, the highest since 2021, fueled by renewed market optimism post-U.S. election. This surge is expected to result in revenues of around $2 billion, marking a 109% year-over-year increase and a 65% rise from the previous quarter. Analysts project earnings of $1.90 per share, reflecting an 83% year-over-year increase, and revenues are expected to rise by 87% from the same quarter last year, reaching $1.78 billion. Coinbase's efforts to diversify its revenue streams are also paying off. Subscription and services revenue is expected to grow by 46.7% year-over-year in Q4 2024, following a 66.3% increase in Q3 2024. This growth underscores the company's successful expansion beyond trading fees. The company's strategic initiatives, including product expansion and improving regulatory clarity, are enhancing its role in the crypto industry. Notably, there has been strong user growth, with a significant rise in monthly active users and wallet activity, reflecting steady demand. In anticipation of these positive developments, Coinbase's stock has surged approximately 81% over the past year, driven by a crypto rally linked to the presidential elections and declining interest rates. Given these factors, Coinbase is well-positioned for a strong performance in its upcoming earnings report, reflecting its robust growth trajectory and strategic advancements in the crypto industry. Entry would go as follows : On market open Target : 326 below the ATH so we can have a protective and reachable take profit SL around the GAP which was formulated above the weak support line! : 215
NASDAQ:COINLong
by DG55Capital
Randstad: A Value Caution in a Shifting LandscapeRandstad NV (AEX: RAND) currently trades around €41.55 with a market cap of approximately €7.62 billion. While many investors may be drawn to its strong dividend history and solid reputation in staffing, a closer look at the fundamentals and macroeconomic outlook suggests that the market may be overestimating its near‐term growth prospects. Declining Profitability A review of Randstad’s recent financials is cause for caution. The company’s net income has shown a marked deterioration over recent years—from €929 million in 2022 to €624 million in 2023 and further down to €272 million on a nine‑month basis in 2024. This steep decline is partly due to mounting operating costs and weakening revenues. From a Buffett perspective, a business with persistent profitability erosion—even one with a storied track record—may have its intrinsic value overstated relative to its current market price. Earnings Release Timing: Pre‐Market Clarity Randstad’s Q4 2024 earnings are scheduled for release on February 12, 2025, at 01:00 AM CET—well before the regular trading hours (pre‑market) on the Amsterdam exchange. This timing can sometimes lead to volatility, as the market digests the numbers before the open. In a scenario where the figures further confirm the declining trends in net income and margins, the pre‑market reaction could set the tone for a downtrend next week.  Macroeconomic Headwinds Beyond company-specific issues, broader economic signals weigh on Randstad’s prospects. Staffing firms are inherently tied to the health of the labor market. Recent reports indicate that while headline figures such as a 143,000-job gain in January might appear robust, underlying trends—including uncertainty over labor market stability and rising concerns over long‑term employment—suggest caution. An environment of higher unemployment (or the fear thereof) can dampen demand for staffing and recruitment services as companies curtail expansion plans. In other words, if fewer people are employed, fewer job openings and less turnover can translate into lower revenues for Randstad over time.  The Technology Disruption Factor Adding another layer of risk, the accelerating pace of technological advancement—particularly in artificial intelligence—could further disrupt traditional staffing. As AI and automation drive efficiencies, many roles traditionally filled through temporary or permanent placement may become obsolete. This transformation not only dampens the immediate demand for recruitment services but also challenges long‑term earnings growth forecasts. When future cash flows are discounted in a model, even a modest shock to growth expectations can result in a present value that is lower than the current market price. Index Inclusion and Credit Concerns Another point to consider is Randstad’s position as the smallest company in the AEX index. Index inclusion is not merely a matter of prestige; it also affects liquidity and investor perception. Losing its spot in the index would heighten uncertainty and could trigger a reassessment of its creditworthiness. A downgraded credit score would raise borrowing costs—further squeezing margins in an already challenging operating environment. A Cautionary DCF Under a Short‑Term Shock A refined look at Randstad’s valuation—one that factors in its debt—offers additional perspective on the risks ahead. In our pessimistic scenario—where net income falls to around €300 million, the perpetual growth rate declines to 2.5%, and the discount rate rises to 7% (reflecting increased credit risk)—the resulting firm value (or enterprise value) comes out to approximately €6.67 billion. However, since this figure represents the value of both debt and equity, we must subtract the net debt to determine the value attributable solely to shareholders. Assuming net debt is roughly €1.38 billion, the estimated equity value would be about €5.29 billion. Dividing that by the 175.14 million shares outstanding gives an estimated share price of around €30. This refined approach, which includes the effect of debt, reinforces the view that a short‑term earnings shock combined with a less favorable long‑term outlook could significantly compress Randstad’s share price. Conclusion In the spirit of Warren Buffett’s careful, long‑term analysis, the case for Randstad appears to be one of caution rather than opportunity. Persistent declines in profitability, headwinds from both macroeconomic signals and technological disruption, and risks associated with its index position all point toward a stock that may be overpriced relative to its intrinsic value. With the pre‑market earnings release scheduled for February 12 (01:00 AM CET), investors should be prepared for potential downside pressure in the coming week if the results confirm these concerns. In summary, while Randstad remains a well‑managed company with a solid track record, its recent decline in profitability, exposure to macroeconomic headwinds, and risks from technological disruption suggest that its current price may be overoptimistic. A simple DCF analysis—even one that factors in debt—underscores this caution: under a short‑term earnings shock scenario, the estimated share price could drop to around €30. For value investors who prize long‑term clarity and rational assessment, these multiple signals warrant a careful reassessment of Randstad’s outlook.
EURONEXT:RANDShort
by The_Prince
1
LLY - in preparation for strong earnings report!Moving on to our next great Stock set up - LLY Eli Lilly and Company (LLY) has demonstrated robust financial performance, driven by its innovative pharmaceutical offerings, particularly in the weight-loss segment. In the third quarter of 2024, the company reported a 20% year-over-year increase in revenue, totaling $11.44 billion. This growth was primarily attributed to a 15% rise in sales volume and a 6% increase in realized prices. Key contributors to this success were the weight-loss drugs Mounjaro and Zepbound. Looking ahead, analysts are optimistic about Eli Lilly's financial trajectory. The company is expected to report fourth-quarter 2024 revenue of approximately $13.5 billion, marking a 45% increase compared to the same period in the previous year. This projection includes significant contributions from Mounjaro and Zepbound, with anticipated revenues of $3.5 billion and $1.9 billion, respectively. Analysts have expressed positive sentiments, with 10 out of 11 surveyed by Visible Alpha rating the stock as a "buy" and setting an average price target of nearly $986, approximately 21% higher than current levels. Overall, Eli Lilly's strategic focus on innovative treatments and its strong product pipeline have positioned the company for continued financial success. So far we believe that the strong fundamentals , and current growth provided by the weight loss drug that has had tremendeous success we would see a positive outcome on their earnigns and growth potetial. Entry: 813 Target 1: 857 - 1st weak resistance Target 2:950 - 2nd strong resistance SL: 750 around the strong support area
NYSE:LLYLong
by DG55Capital
8
Technically, Weekly candle close: Fundamentally, Better EPSWe need the two signals. This week it touched the lower trenline of daily channel. yet no candlestick confirmation. 1st, candle stick pattern close on weekly basis. 2nd: Quaterly report is expected in next two weeks which will confirm the technical movement. A positive report will boost the bullish sentiment to first @70 area and upon break the trenline resistance, it will move further to 100.... matlab century to marega.. A negative report will dump it and price may drop to its monthly fibb level at 60% around 45 area. Lets' wait and see. I will think about the position next week upon weekly candlestick closure.
PSX:ILP
by hameedops